Proceeds from non-marketable securities
Eli Lilly Proceeds from non-marketable securities decreased by 76.3% to $132.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 137.4%, from $55.60M to $132.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from non-marketable securities shows an upward trend with a 4.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher proceeds suggest successful exits from strategic investments or a shift toward liquidating non-core assets to generate cash.
Detailed definition
This metric tracks cash inflows resulting from the sale, redemption, or maturity of investments that do not have a readi...
Peer comparison
Often found in the investing section of cash flow statements for companies with significant corporate venture capital or strategic investment arms.
cf_aapl_proceeds_from_non_marketable_securitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $200.00M | $200.00M | $200.00M | $81.40M | $87.10M | $83.10M | $90.60M | $281.90M | $106.50M | $87.80M | $31.90M | $70.50M | $179.60M | $67.90M | $55.60M | $71.60M | $204.30M | $556.10M | $132.00M |
| QoQ Change | — | +0.0% | +0.0% | -59.3% | +7.0% | -4.6% | +9.0% | +211.1% | -62.2% | -17.6% | -63.7% | +121.0% | +154.8% | -62.2% | -18.1% | +28.8% | +185.3% | +172.2% | -76.3% |
| YoY Change | — | — | — | — | -56.5% | -58.5% | -54.7% | +246.3% | +22.3% | +5.7% | -64.8% | -75.0% | +68.6% | -22.7% | +74.3% | +1.6% | +13.8% | +719.0% | +137.4% |
Proceeds from non-marketable securities at Other Companies
Frequently Asked Questions
- What is Eli Lilly's proceeds from non-marketable securities?
- Eli Lilly (LLY) reported proceeds from non-marketable securities of $132.00M in Q4 2025.
- How has Eli Lilly's proceeds from non-marketable securities changed year-over-year?
- Eli Lilly's proceeds from non-marketable securities increased by 137.4% year-over-year, from $55.60M to $132.00M.
- What is the long-term trend for Eli Lilly's proceeds from non-marketable securities?
- Over 4 years (2021 to 2025), Eli Lilly's proceeds from non-marketable securities has grown at a 4.8% compound annual growth rate (CAGR), from $800.00M to $964.00M.
- What does proceeds from non-marketable securities mean?
- Cash received from selling or redeeming private or non-traded investments.